UPDATE Thursday, March 24, 2022, 2:10 p.m.—A Gilead spokesperson disputed AIDS Healthcare Foundation’s statement that, under Gilead’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments, the company will give 340B discounts to covered entities only “if they turn over sensitive data about the providers’ patients. Providers who don’t submit this data are shut out.”
Gilead said that entities that decide not to provide claims level data on their contract pharmacy utilization and that do not have an in-house pharmacy “will have the option to select a single contract pharmacy location.”
AIDS Healthcare Foundation (AHF), the world’s largest AIDS provider organization, held a demonstration yesterday in front of drug manufacturer Gilead’s San Francisco Bay area headquarters protesting the company’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
